Franklin Biolabs Achieves CLIA Certification for AAV NAb Testing
Learn more

Advanced In Vivo Imaging Techniques for Tracking Mesenchymal Stem Cell (MSC) Migration and Engraftment

PROVEN INTELLIGENCE ACCELERATING NEXT-GENERATION THERAPIES

Advanced In Vivo Imaging Techniques for Tracking Mesenchymal Stem Cell (MSC) Migration and Engraftment

In Vivo Imaging for Mesenchymal Stem Cell (MSC) Biodistribution

CELL & GENE | RNA | BIOLOGICS

Proven Intelligence Accelerating Next-Generation Therapies.

A blue-toned image of white lab rats in their cages within a laboratory or vivarium setting, likely for scientific research or testing.

A close-up shot of a modern bioreactor system and control unit from Pall Corporation in a clean laboratory environment.

Executive Summary

Advanced in vivo imaging strategies are employed to quantify Mesenchymal Stem Cell (MSC) migration, engraftment, and persistence. A multi-modal approach combining bioluminescence imaging (BLI), fluorescence imaging (FLI), and SPECT-CT generates robust data packages suitable for Investigational Medicinal Product Dossier (IMPD) and IND submissions. The focus is on generating reproducible, quantitative data to de-risk clinical translation for somatic cell therapy programs.

Technical FAQ: MSC In Vivo Imaging

    What is the primary challenge in tracking MSCs in vivo?

    The main difficulty is differentiating between viable, engrafted cells and cleared or dead cells. Standard biodistribution methods like qPCR can detect cellular DNA but cannot confirm cell viability or function. Advanced imaging provides longitudinal data on viable cell populations.

    Which imaging modality is best for quantitative analysis?

    For deep-tissue quantitative data, Single-Photon Emission Computed Tomography (SPECT-CT) is highly effective when cells are labeled with a suitable radionuclide. Bioluminescence Imaging (BLI) offers excellent sensitivity for tracking cell viability over time, though deep-tissue signal attenuation can be a factor. A combined approach often yields the most complete dataset.

    How does imaging support regulatory submissions in the EU?

    For ATMP submissions to agencies like the MHRA, robust data on cell fate, biodistribution, and persistence is expected. In vivo imaging provides direct visual evidence of cell trafficking and non-target tissue biodistribution, strengthening the safety and efficacy narrative within an IMPD.

    Can these techniques be applied in GxP-compliant studies?

    Yes, all imaging procedures and data analyses can be conducted within a GxP framework. The development and qualification of these methods are performed in a phase-appropriate manner to support IND-enabling toxicology studies.

The Challenge: Quantifying MSC Fate Post-Administration

Verifying the biodistribution, migration, and long-term engraftment of MSCs is a frequent obstacle for developers of somatic cell therapies. A standard, one-size-fits-all preclinical testing template does not exist for these programs. A data-driven preclinical strategy, tailored to the specific MSC product and target indication, is required to satisfy regulatory expectations.

Histology provides a terminal snapshot of cell location, but it fails to capture the dynamic process of cell migration and persistence. To build a comprehensive safety and efficacy profile, sponsors need longitudinal data that visualizes the behavior of viable cells over time in the same subject. This provides high-fidelity in vivo intelligence for complex modalities.

A stylized 3D rendering of a DNA double helix, composed of light-colored spheres on a translucent blue backbone, set against a soft-focus, light blue background.

A close-up of a scientist in blue gloves gently holding a small, white laboratory mouse, likely in a research setting.

A Multi-Modal Imaging Strategy

We employ a suite of validated imaging techniques to construct a complete picture of MSC behavior. This approach is informed by foundational work in noninvasive imaging of gene transfer, which established methods for quantitative in vivo monitoring (PMID: 12639305).

Our strategy includes:

  • Bioluminescence Imaging (BLI): MSCs are transduced with a luciferase reporter gene. This allows for highly sensitive, longitudinal tracking of viable cell populations, as only metabolically active cells will produce a signal.

  • Fluorescence Imaging (FLI): Using fluorescent protein reporters (e.g., GFP, mCherry) or cell-permeant dyes, FLI provides high-resolution optical data, particularly for superficial tissue engraftment.

  • SPECT-CT Imaging: For absolute quantification and 3D anatomical localization, cells are labeled with a radionuclide like Indium-111. This technique provides precise data on cell distribution throughout the body, including deep tissues.

This combination of methods addresses key questions about your therapeutic candidate, building on established principles of targeting progenitor cells in vivo to achieve a durable therapeutic effect (PMID: 14577924). The resulting data package provides clear evidence of on-target delivery and persistence.

Animal Welfare and Enhanced Responsibility

All in vivo procedures are conducted in our >100,000 sq ft facility with a deep commitment to animal welfare. Our facilities are USDA compliant, and all programs are designed to meet the standards of AAALAC International, strictly adhering to the 3Rs principle (Replacement, Reduction, and Refinement). For relevant programs, we select nonhuman primate (NHP) models with an immune system that closely mirrors the human response to assess immunogenicity.

Our enhanced housing and enrichment programs are designed to support animal well-being throughout the in-life phase of a study.

A promotional graphic for Franklin BioLabs showcasing a list of their notable scientific publications in preclinical and translational research.

A marketing fact sheet from Franklin Biolabs about the scientific benefits of Mauritian cynomolgus macaques for preclinical research, featuring a photo of the primates.

From Preclinical Data to Regulatory Approval

Franklin Biolabs has a demonstrated record of guiding programs to successful regulatory filings, a process we typically complete within an 18-24 month timeline. While the Franklin Biolabs brand launched in 2024, our scientific leadership’s work has contributed to a 100% successful IND rate since 2019. Our experience with both FDA and international bodies, including MHRA submissions, ensures your preclinical data package is built for regulatory acceptance from day one.

Technical Visualization: Multi-Modal MSC Imaging Workflow

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities